| Name | Title | Contact Details |
|---|
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.
Medelis is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MediSpin Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our AI & AR powered technology reduces medical practice overhead, accelerates patient throughput, improves efficiency, and speeds up data collection.
Longeveron is a clinical stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. Their lead investigational product is Lomecel B™, which is derived from culture-expanded medicinal signaling cells ...